Expres2ion scales up in vaccination market with new product: "A clear competitive advantage"
After years of development, biotech company Expres2ion is ready with a new version of its manufacturing system, which according to the company CEO is going to "significantly" strengthen the company's position and the development of the vaccination and immune therapy market.
BY ALBERT RØNNING-ANDERSSON, MEDWATCH
It has taken more than six years but Expres2ion has finally crossed the finish line.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
